BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months

Reuters01-14

BRIEF-<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months

Jan 14 (Reuters) - Clearmind Medicine Inc CMND.O:

CLEARMIND MEDICINE INC - TOPLINE RESULTS FROM SECOND COHORT OF CMND-100 EXPECTED IN COMING MONTHS

Source text: ID:nGNXbnvDZf

Further company coverage: CMND.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603611416?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603611416","market":"fut","top_or_hot":-1,"title":"BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months</title></head><body><p><span>Jan 14 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine</a> Inc <span>CMND.O</span>:</p><ul><li><p>CLEARMIND MEDICINE INC - TOPLINE RESULTS FROM SECOND <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF CMND-100 EXPECTED IN COMING MONTHS</p></li></ul><p>Source text: <span>ID:nGNXbnvDZf</span></p><p>Further company coverage: <span>CMND.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months</title></head><body><p><span>Jan 14 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine</a> Inc <span>CMND.O</span>:</p><ul><li><p>CLEARMIND MEDICINE INC - TOPLINE RESULTS FROM SECOND <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF CMND-100 EXPECTED IN COMING MONTHS</p></li></ul><p>Source text: <span>ID:nGNXbnvDZf</span></p><p>Further company coverage: <span>CMND.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1UX:1","article_id":"2603611416","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603611416","pubTimestamp":1768399341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming MonthsJan 14 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC - TOPLINE RESULTS FROM SE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CMND":"Clearmind Medicine, Inc."},"translate_title":"简介-Clearmind Medicine Inc-预计在未来几个月内获得第二批CMND-100的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":0.9},"content_text":"BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming MonthsJan 14 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC - TOPLINE RESULTS FROM SECOND COHORT OF CMND-100 EXPECTED IN COMING MONTHSSource text: ID:nGNXbnvDZfFurther company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603611416","isCrawlerRequest":true}